In this special edition of Diabetes Core Update, host Neil Skolnik, MD, explores the timely and critical topic of compounded medications in diabetes care. Dr. Skolnik is joined by John Hertig, PharmD, MS, CPPS, Associate Professor at the Butler University College of Pharmacy and Health Sciences, and Ed Hernandez, Executive Vice President and President of Manufacturing Operations at Eli Lilly & Company.

Together, they discuss the role of compounded medications, the benefits and risks associated with their use, and the importance of ensuring quality and safety standards in the compounding process. This episode offers valuable insights for clinicians navigating the complexities of compounded therapies and provides practical considerations for patient care.

This podcast is the first of a four-part series, “Compounding Concerns: Diabetes and Obesity Medications” in Diabetes Core Update’s 12-episode “Elevating Diabetes Care: Advanced Clinical Insights” program.

This 3-episode series and the “Elevating Diabetes Care: Advanced Clinical Insights Program” are supported by Lilly.   

The views, thoughts, and opinions expressed in this podcast belong solely to the individual speakers and do not necessarily reflect the views or opinions of Eli Lilly and Company or any of its affiliates.

Presented by:

• Neil Skolnik, MD – Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington–Jefferson Health
• John Hertig, PharmD, MS, CPPS – Associate Professor, Butler University College of Pharmacy and Health Sciences
• Ed Hernandez – Executive Vice President, Eli Lilly & Company; President of Manufacturing Operations at Lilly

Selected References:

Compounded GLP 1 and Dual GIP/GLP 1 Receptor Agonists: A Statement from the American Diabetes Association. Diabetes Care December 2, 2024;  dci240091 https://doi.org/10.2337/dci24-0091 PubMed: 39620926

FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.  US FDA Website ( current as of 12/18/2024)